Utama › Dermatomiositis
Kajian klinikal Dermatomiositis sedang mengambil peserta di AS
26 kajian untuk Dermatomiositis sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Durham, NC8 kajian
- Washington, DC7 kajian
- New York City, NY5 kajian
- Pittsburgh, PA5 kajian
- Houston, TX5 kajian
- Boston, MA5 kajian
- Philadelphia, PA4 kajian
- Baltimore, MD4 kajian
- Miami, FL4 kajian
- Cleveland, OH3 kajian
- Kansas City, KS3 kajian
- Jacksonville, FL3 kajian
- Aurora, CO3 kajian
- New Haven, CT3 kajian
- Phoenix, AZ3 kajian
Mengikut negeri
- Arizona4 kajian
- California9 kajian
- Colorado4 kajian
- Connecticut3 kajian
- Florida7 kajian
- Illinois3 kajian
- Kansas4 kajian
- Maryland9 kajian
- Massachusetts5 kajian
- New York6 kajian
- North Carolina8 kajian
- Ohio5 kajian
- Pennsylvania7 kajian
- Texas6 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
Mengambil pesertaFasa 2
Umur 18 hingga 60 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07111065Environmental Risk Factors for the Anti-synthetase Syndrome
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 2 hingga 100 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT01276470A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06455449Natural History of Inflammatory Muscle Diseases
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 2 hingga 120 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT05738824Adult and Juvenile Myositis
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 2 hingga 100 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT00017914Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT03816345RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Mengambil pesertaFasa 2/3
Umur 6 hingga 75 · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06154252A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Mengambil pesertaFasa 1
Umur 18 hingga 70 · Semua jantina · Dikemas kini 15 Sep 2026 · NCT06916806A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT05895786A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Mengambil pesertaFasa 1
Umur 18 hingga 74 · Semua jantina · Dikemas kini 10 Sep 2026 · NCT07085104FT839 in Autoimmune Diseases
Mengambil pesertaFasa 1/2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07800871A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT06698796Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT07486869Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 27 Jul 2026 · NCT07089121Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Mengambil pesertaFasa 1
Umur 18 hingga 85 · Semua jantina · Dikemas kini 22 Jul 2026 · NCT06371417A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Jul 2026 · NCT07115745Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Jul 2026 · NCT07138898Intralesional Injection of STS in Treatment of Calcinosis
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Mei 2026 · NCT06672822Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Apr 2026 · NCT07160205Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Mac 2026 · NCT02945345Rheumatology Patient Registry and Biorepository
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 hingga 99 · Semua jantina · Dikemas kini 13 Feb 2026 · NCT04402086A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Feb 2026 · NCT07403188MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Mengambil pesertaKajian pemerhatian
Umur 7 ke atas · Semua jantina · Dikemas kini 28 Jan 2026 · NCT07374107Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Mengambil pesertaFasa 2
Umur 18 hingga 89 · Semua jantina · Dikemas kini 8 Okt 2025 · NCT06857240Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Mengambil pesertaFasa 1
Umur 25 hingga 72 · Semua jantina · Dikemas kini 21 Mei 2025 · NCT06298019Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.